1. Academic Validation
  2. PPARG-centric transcriptional re-wiring during differentiation of human trophoblast stem cells into extravillous trophoblasts

PPARG-centric transcriptional re-wiring during differentiation of human trophoblast stem cells into extravillous trophoblasts

  • Nucleic Acids Res. 2025 Jul 19;53(14):gkaf669. doi: 10.1093/nar/gkaf669.
Qingqing Guo 1 Joonhyuk Choi 1 Muyoung Lee 1 Jonghwan Kim 1 2
Affiliations

Affiliations

  • 1 Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, United States.
  • 2 Center for Systems and Synthetic Biology, The University of Texas at Austin, Austin, TX 78712, United States.
Abstract

Peroxisome Proliferator-activated Receptor gamma (PPARG) is a nuclear receptor family transcription factor (TF) critical for adipogenesis, lipid metabolism, Insulin sensitivity, and inflammation. It has also been known to play essential roles in trophoblast development and placentation. Dysregulation of PPARG in trophoblast differentiation has been implicated in pregnancy complications, such as pre-eclampsia and gestational diabetes. However, the molecular mechanisms of PPARG-dependent target gene regulation and its interactions with Other regulatory factors during human trophoblast differentiation remain unclear. Using human trophoblast stem cells (TSCs), mimicking placental cytotrophoblasts (CTs), and their differentiation into extravillous trophoblasts (EVTs) as our models, we reveal that PPARG has cell-type-specific targets in TSCs and EVTs. We also find that while PPARG is essential for both TSC self-renewal and EVT differentiation, only its role in EVT differentiation is ligand sensitive and requires ligand-binding domain (LBD)-mediated transcriptional activity, whereas its function in TSC self-renewal appears to be ligand insensitive. Combined analysis with chromosomal targets of previously defined key TFs in TSCs and EVTs shows that PPARG forms trophoblast cell-type-specific regulatory circuitries, leading to differential target gene regulation via transcriptional re-wiring during EVT differentiation. Additionally, the enhanced invasiveness of EVTs treated with a PPARG agonist suggests a potential connection between PPARG pathways and human placenta accreta.

Figures
Products